← Back to news

Markets

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Y

Tether Says It Will Be Audited By Big Four Accounting Firm—But Won't Say Which One

Y

Core & Main Q4 Earnings Call Highlights

Y

Smithfield Foods Q4 Earnings Call Highlights

Y

Cadeler A/S H2 Earnings Call Highlights

Y

LENZ Therapeutics Q4 Earnings Call Highlights

Y

Hesai Group Q4 Earnings Call Highlights

Y

RadNet (RDNT) Acquires Gleamer for €230 Million

Y

Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target

Y

Waters (WAT) Prices $3.5 Billion Senior Notes Offering

Y

Morgan Stanley Lowers Personalis (PSNL) Price Target to $10

Y

CareDx (CDNA) Launches AI-based Platform VANTx

Y

TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213

Y

Agilent Technologies (A) to Acquire Biocare Medical for $950M

Y

Natera (NTRA) Launches Zenith Genomic Assay

Y

Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial

Y

Danaher (DHR) Projects 2026 Revenue Growth at TD Cowen 46th Annual Health Care Conference

Y

Why NexGen Energy’s Rook I Approval Could Mark a Turning Point for Its Uranium Buildout

Y

How Deep Yellow’s Tumas Progress Is Shaping the Next Phase of Its Uranium Development Story

Y

Why HC Wainwright Sees Uranium Energy Well Positioned for a Bigger Production Ramp

Y

How Energy Fuels’ 2026 Outlook Framed 2025 as a Transformational Year for the Company

Y

Why enCore Energy’s 2025 Production Gains Matter for Its Contract-Delivery Strategy

Y

'Buy the Dip' Signal on Uranium Stock Has Never Been Wrong

Y

Why Lenz Therapeutics Stock Crashed Today

Y

Investors Are Betting on an Interest Rate Hike That’s Really Not That Likely

Y

Xcel Energy Could Hit $89 by Year-End as UBS Argues Wildfire Risks Are Already Priced Into $76.75 Stock

Y

3 Dividend Stocks to Buy and Hold Forever

Y

Replenish Nutrients builds a licensing flywheel to scale high-margin fertilizer IP

Y

Mueller Water Director Buys $739K in Shares — A Bullish Signal for This Water Infrastructure Play?

Y

SanDisk Stock’s Breakout Looks Overdone—Unless the AI Supercycle Is Real

Y

How Oklo’s DOE Milestone Advanced Its Push Into Domestic Isotope Production

Y

Why Ur-Energy’s Higher 2026 Spending Hasn’t Derailed Wall Street’s Broader View

Y

How NuScale Is Expanding Its Nuclear Pitch Beyond Power Generation and Into Industrial Heat

Y

Why Denison Mines’ Construction Timeline Is Central to the Bull Case After TD’s Target Hike

Y

How Centrus Thinks Palantir Can Help Cut Costs in Its Enrichment Expansion Effort

Y

Wall Street Thinks These 5 Stocks Could Be the Next Big Winners

Y

BofA Initiates Nebius At Buy. AI Computing Firm Positioned As 'Share-Taker.'

Y

Jim Cramer on Enterprise Products Partners: “This Is a Pipeline Company That I Think in Many Ways Is the Best Run of All of Them”

Y

Jim Cramer Says “You Don’t Buy Enbridge for Its LNG Exposure, You Buy It for the Gas Pipelines and the Bountiful Dividend”

Y

Jim Cramer on Cheniere Energy: “It’s the Cleanest Play on LNG, and That Stock’s Actually Not Even That Expensive”

Y

Jim Cramer Notes “Sempra Is Mainly a Utility and They Want to Be More of a Pure Play.”

Y

Jim Cramer on FedEx Corporation: “I Think the Stock Deserves to Go Higher, Maybe Appreciably Higher”

Y

Jim Cramer on CAVA Group: “I Never Understood Why It Was All the Way Down”

Y

Jim Cramer on Corning Incorporated: “We’ll Pick Some Up After the Sell, Not Before”

Y

Jim Cramer on Venture Global: “This Is the One You Want to Own If You’re a True Believer”

Y

Jim Cramer Recommends a Caller to Sell Half of Their Coterra Energy Position and “Let the Rest Run”

Y

Jim Cramer on TechnipFMC plc: “It’s Still Inexpensive Versus the Others in the Cohort”

Y

Jim Cramer on Innovative Aerosystems: “That’s a Very Aggressive Growth Stock”

Y

Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”

Y

Jim Cramer on Lam Research: “You’ve Got a Winner in Lam Research”

Y